Celcuity's breast cancer drug received approval from the Food and Drug Administration. "Clecuity Gets FDA Approval for Breast Cancer Drug," at 5:33 p.m. ET, misspelled the company name in the headline.
Celcuity's breast cancer drug received approval from the Food and Drug Administration. "Clecuity Gets FDA Approval for Breast Cancer Drug," at 5:33 p.m. ET, misspelled the company name in the headline.
(END) Dow Jones Newswires
July 14, 2026 18:40 ET (22:40 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
The articles, information, and content displayed on this webpage may
The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that…
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a…
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s…
Celcuity stock crashed Tuesday on disappointing results for its three-drug approach to advanced breast cancer.
Celcuity expands VIKTORIA-2 to endocrine-sensitive breast cancer patients and advances injectable gedatolisib formulation.
Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
Celcuity gains FDA approval for closely watched breast cancer drug
Celcuity's breast cancer drug approved, its first
FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer - Pfizer (NYSE:PFE)
Star Padcev-Keytruda combo expands bladder cancer reach with FDA approval, pressuring AstraZeneca
